Anti-PCSK9 monoclonal antibody treatment of lipoprotein disorders

Drugs of the Future

Volumn 38, Issue 7, 2013, Pages 451-459

  Stein, E A ^a   Wasserman, S M ^b   Dias, C ^b   Scott, R ^b   Raal, F ^c  

^a Metabolic and Atherosclerotic Research Center   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

AMG 145; Clinical trials; Lipoprotein disorders; Monoclonal antibody

Indexed keywords

AMG 145; ATORVASTATIN; EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AMG 145; ROSUVASTATIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; INFLUENZA; INJECTION SITE BLEEDING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84930540759     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.07.1981967     Document Type: Article

References (17)

1. Goldstein, J.L., Hobbs, H.H., Brown, M.S. Familial hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease, 2001, 2863-913.
2. Abifadel, M., Varret, M., Rabès, J.P. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34(2): 154-6.
3. Maxwell, K.N., Breslow, J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101(18): 7100-5.
4. Rashid, S., Curtis, D.E., Garuti, R. et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci U S A 2005, 102(15): 5374-9.
5. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354(12): 1264-72.
6. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79(3): 514-23.
7. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., Burnett, J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193(2): 445-8.
8. Lagace, T.A., Curtis, D.E., Garuti, R. et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116(11): 2995-3005.
9. Seidah, N.G., Benjannet, S., Wickham, L. et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100(3): 928-33.
10. Tremblay, A.J., Lamarche, B., Lemelin, V. et al. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res 2011, 52(3): 558-65.
11. Benjannet, S., Rhainds, D., Essalmani, R. et al. NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279(47): 48865-75.
12. Tveten, K., Holla, O.L., Cameron, J. et al. Interaction between the ligandbinding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification. Hum Mol Genet 2012, 21(6): 1402-9.
13. Dias, C.S., Shaywitz, A.J., Wasserman, S.M. et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012, 60(19): 1888-98.
14. Koren, M.J., Scott, R., Kim, J.B. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012, 380(9858): 1995-2006.
15. Giugliano, R.P., Desai, N.R., Kohli, P. et al.; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380(9858): 2007-17.
16. Raal, F., Scott, R., Somaratne, R., Bridges I., Li, G., Wasserman, S.M., Stein, E.A. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126(20): 2408-17.
17. Sullivan, D., Olsson, A.G., Scott, R. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012, 308(23): 2497-506.